12:00 AM
 | 
Mar 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Quad elvitegravir/cobicistat/emtricitabine/tenofovir: Additional Phase III data

Additional data from the double-blind, U.S. and Puerto Rican Phase III Study 102 trial in 700 treatment-naive patients showed that once-daily Quad led to significantly smaller increases from baseline in total cholesterol and LDL-C at week 48 vs. Atripla emtricitabine/tenofovir/efavirenz (10 and 10 mg/dL, respectively, vs. 19 and 17 mg/dL; p<0.001 and p=0.001). Last year, Gilead reported that Quad met the primary endpoint of non-inferiority to Atripla in...

Read the full 330 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >